ObjectivesTo examine prevalence and risk factors for post-COVID-19 condition (PCC) in a paediatric population.MethodsThe study included patients aged 5–17 years with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection between 1 March 2021 and 30 April 2022 and matched non-infected controls from Yao City, Japan. We compared parent-reported symptoms persisting ≥2 months (present at 3 months post-infection for patients) between the groups. COVID-19 vaccination data was obtained from the Vaccination Registry.ResultsAmong 8,167 invited individuals, 3,141 (1,800 cases, mean age: 10.4 years, 46.1% females; 1,341 controls, mean age 10.5 years, 47.1% females) participated. Patients had elapsed average 273 (185–605) days from infection, and 1,708 (94.9%) experienced mild acute symptoms. Patients had higher odds of having persistent symptoms than did controls (6.3% vs 2.2%, adjusted odds ratio [aOR]: 3.15, 95% confidence interval: 2.08–4.77), with 53.6% of them reporting current disruption due to the symptoms. Older age, low household income, pre-existing allergy, and autonomic nervous system disease were associated with increased risks of developing PCC; two prior vaccination doses reduced these risks (aOR: 0.52, 0.29–0.93).ConclusionsSARS-CoV-2 infection, including omicron infections heighten persistent symptom risk in the paediatric population, necessitating preventive strategies, notably vaccination.
No takes yet. Share an insight, caveat, or question.
Hosozawa et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: